Cargando…

Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors

PURPOSE: Radical resection is paramount for curative oncological surgery. Fluorescence-guided surgery (FGS) aids in intraoperative identification of tumor-positive resection margins. This study aims to assess the feasibility of urokinase plasminogen activator receptor (uPAR) targeting antibody fragm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baart, Victor M., van Manen, Labrinus, Bhairosingh, Shadhvi S., Vuijk, Floris A., Iamele, Luisa, de Jonge, Hugo, Scotti, Claudia, Resnati, Massimo, Cordfunke, Robert A., Kuppen, Peter J. K., Mazar, Andrew P., Burggraaf, Jacobus, Vahrmeijer, Alexander L., Sier, Cornelis F. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970952/ https://www.ncbi.nlm.nih.gov/pubmed/34642899 http://dx.doi.org/10.1007/s11307-021-01657-2

Ejemplares similares

CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy
por: Linders, Daan, et al.
Publicado: (2021)

Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study
por: Boonstra, Martin C, et al.
Publicado: (2014)

Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using a Fluorescently Labelled Anti-CEA Nanobody Probe: A Preclinical Study
por: van Manen, Labrinus, et al.
Publicado: (2023)

Glycan-Based Near-infrared Fluorescent (NIRF) Imaging of Gastrointestinal Tumors: a Preclinical Proof-of-Concept In Vivo Study
por: Houvast, Ruben D., et al.
Publicado: (2020)

uPAR directed-imaging of head-and-neck cancer
por: Baart,, Victor M., et al.
Publicado: (2017)

uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery
por: Boonstra, Martin C., et al.
Publicado: (2015)

uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions
por: Mahmood, Niaz, et al.
Publicado: (2020)

Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging
por: Yang, Dongzhi, et al.
Publicado: (2016)

Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer
por: de Muijnck, Cansu, et al.
Publicado: (2020)

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues
por: de Jonge, Hugo, et al.
Publicado: (2021)

Quantitative dynamic near-infrared fluorescence imaging using indocyanine green for analysis of bowel perfusion after mesenteric resection
por: Meijer, Ruben P. J., et al.
Publicado: (2021)

Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)
por: Xu, Xiang, et al.
Publicado: (2014)

Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue
por: Boogerd, LSF, et al.
Publicado: (2017)

Small Molecules for Multi-Wavelength Near-Infrared Fluorescent Mapping of Regional and Sentinel Lymph Nodes in Colorectal Cancer Staging
por: Baart, Victor M., et al.
Publicado: (2020)

Human antibody V(H) domains targeting uPAR as candidate therapeutics for cancers
por: Chu, Xiaojie, et al.
Publicado: (2023)

Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas
por: Peng, Luogen, et al.
Publicado: (2023)

In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer
por: Hoogstins, Charlotte ES, et al.
Publicado: (2017)

Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals
por: Reijers, Joannes A. A., et al.
Publicado: (2019)

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
por: Münz, Markus, et al.
Publicado: (2010)

A dark side to NS1 antibodies?
por: Robbiani, Davide F., et al.
Publicado: (2021)

Integrin is on uPAR to unleash cells
por: LeBrasseur, Nicole
Publicado: (2003)

uPAR's signaling two step
por: Leslie, Mitch
Publicado: (2007)

The Many Spaces of uPAR: Delivery of Theranostic Agents and Nanobins to Multiple Tumor Compartments through a Single Target
por: O'Halloran, Thomas V., et al.
Publicado: (2013)

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
por: Harel, Efrat T., et al.
Publicado: (2019)

Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
por: de Geus, Susanna WL, et al.
Publicado: (2017)

Data on the regulation of moesin and merlin by the urokinase receptor (uPAR): Model explaining distal activation of integrins by uPAR
por: Degryse, Bernard, et al.
Publicado: (2017)

High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions
por: Lourenço, André Luiz, et al.
Publicado: (2023)

Correction: Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)
Publicado: (2014)

Correction: Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)
Publicado: (2014)

Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy
por: van Dam, Martijn A., et al.
Publicado: (2021)

uPAR: An Essential Factor for Tumor Development
por: Lv, Tao, et al.
Publicado: (2021)

Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221
por: Falkenberg, Natalie, et al.
Publicado: (2015)

A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies
por: Sánchez-Zuno, Gabriela Athziri, et al.
Publicado: (2021)

Side-By-Side Evaluation of Three Commercial ELISAs for the Quantification of SARS-CoV-2 IgG Antibodies
por: Girl, Philipp, et al.
Publicado: (2022)

Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment
por: Vuijk, F. A., et al.
Publicado: (2020)

Targeted drug delivery for cancer therapy: the other side of antibodies
por: Firer, Michael A, et al.
Publicado: (2012)

Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation
por: Reijers, Joannes A. A., et al.
Publicado: (2016)

HIV-1 Infected Lymphoid Organs Upregulate Expression and Release of the Cleaved Form of uPAR That Modulates Chemotaxis and Virus Expression
por: Nebuloni, Manuela, et al.
Publicado: (2013)

Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer
por: Baart, V. M., et al.
Publicado: (2020)

Crystal structure and cellular functions of uPAR dimer
por: Yu, Shujuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cskbkb9kad1pci01dlv807b432